Sorafenib was associated with increased rates of chronic GVHD, consistent with preclinical evidence suggesting that FLT3 inhibition may augment graft-versus-leukemia effects [81].A Chinese multicenter trial provided confirmatory evidence, also showing reduced relapse and improved survival with sorafenib maintenance [82]. The gene discussed is FLT3; the disease is leukemia.